Fusen Pharmaceutical Co., Ltd. (HK:1652)
:1652
Want to see HK:1652 full AI Analyst Report?
1652 Stock Chart & Stats
HK$0.80
-HK$0.03(-4.41%)
At close: 4:00 PM EST
HK$0.80
-HK$0.03(-4.41%)
Day’s Range― - ―
52-Week RangeHK$0.30 - HK$1.75
Previous CloseN/A
Volume70.00K
Average Volume (3M)1.23M
Market Cap
HK$786.69M
Enterprise ValueHK$930.13M
Total Cash (Recent Filing)HK$83.88M
Total Debt (Recent Filing)HK$324.34M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding739,301,000
10 Day Avg. Volume642,000
30 Day Avg. Volume1,233,253
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)1.48
Price to Sales (P/S)1.94
P/FCF Ratio7.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Cash GenerationOperating cash flow was positive and sizable in 2024 and 2025, producing recurring free cash flow in the most recent years. Sustained cash generation over the next 2–6 months supports working capital, funds necessary product investment or debt servicing, and reduces short-term refinancing pressure despite historical volatility.
Top-line RecoveryRevenue rebounded in 2025 after the sharp 2024 contraction, signaling regained demand or improved execution. A durable top-line recovery helps spread fixed costs, creates scope for margin recovery, and is a prerequisite for restoring sustainable profitability if the company can keep growth consistent across core product lines.
Balance-sheet CushionEquity remains positive and the asset base is relatively stable, with leverage improving modestly in 2025. This provides a buffer that preserves operational continuity, supports access to credit, and gives management time to execute a profit turnaround without immediate solvency risk, enhancing medium-term resilience.
Bears Say
Sustained LossesThe company moved from profits in 2020–2021 to sustained losses from 2022–2025, with 2025 still showing a small net loss. Persistent losses erode retained earnings, constrain capital available for R&D or commercialization, and mean management must deliver structural profitability improvements to avoid long-term solvency and investment capacity risks.
Margin CompressionGross margin compressed notably in 2025 while operating profit remained negative, indicating pressure on pricing or rising costs. Margin deterioration makes earnings recovery harder even with revenue growth, reduces free cash flow conversion, and increases reliance on either cost cuts or higher-margin products for a durable improvement.
Higher LeverageDebt relative to equity rose to roughly parity in 2024 before modest improvement in 2025, increasing leverage versus earlier years. Elevated leverage reduces financial flexibility, raises interest and refinancing risk, and narrows the margin for error if earnings remain weak, making the recovery path more dependent on cash generation consistency.
Fusen Pharmaceutical Co., Ltd. News
1652 FAQ
What was Fusen Pharmaceutical Co., Ltd.’s price range in the past 12 months?
Fusen Pharmaceutical Co., Ltd. lowest stock price was HK$0.29 and its highest was HK$1.75 in the past 12 months.
What is Fusen Pharmaceutical Co., Ltd.’s market cap?
Fusen Pharmaceutical Co., Ltd.’s market cap is HK$786.69M.
When is Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date?
Fusen Pharmaceutical Co., Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 89 days.
How were Fusen Pharmaceutical Co., Ltd.’s earnings last quarter?
Fusen Pharmaceutical Co., Ltd. released its earnings results on Mar 31, 2026. The company reported HK$0.017 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.017.
Is Fusen Pharmaceutical Co., Ltd. overvalued?
According to Wall Street analysts Fusen Pharmaceutical Co., Ltd.’s price is currently Overvalued.
Does Fusen Pharmaceutical Co., Ltd. pay dividends?
Fusen Pharmaceutical Co., Ltd. pays a Notavailable dividend of HK$0.004 which represents an annual dividend yield of N/A. See more information on Fusen Pharmaceutical Co., Ltd. dividends here
What is Fusen Pharmaceutical Co., Ltd.’s EPS estimate?
Fusen Pharmaceutical Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Fusen Pharmaceutical Co., Ltd. have?
Fusen Pharmaceutical Co., Ltd. has 739,301,000 shares outstanding.
What happened to Fusen Pharmaceutical Co., Ltd.’s price movement after its last earnings report?
Fusen Pharmaceutical Co., Ltd. reported an EPS of HK$0.017 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -3.226%.
Which hedge fund is a major shareholder of Fusen Pharmaceutical Co., Ltd.?
Currently, no hedge funds are holding shares in HK:1652
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Fusen Pharmaceutical Co., Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-13.18%
12-Months-Change
Fundamentals
Return on Equity
-3.39%
Trailing 12-Months
Asset Growth
6.80%
Trailing 12-Months
Company Description
Fusen Pharmaceutical Co., Ltd.
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuanghuanglian oral solutions and Shuanghuanglian injections; and flunarizine hydrochloride capsules and compound ferrous sulfate granules, as well as Yuanhu Zhitong oral solutions, Ganweikang tablets, and Yixinkang tablets. In addition, it researches, develops, produces, and sells various proprietary Chinese medicines and western medicine products for the treatment of cold and fever, cardiovascular diseases, and anemia. Further, the company offers business management and consulting services. Fusen Pharmaceutical Company Limited was founded in 2003 and is headquartered in Nanyang, China.
Technical Analysis
Extrawell Pharmaceutical Holdings Limited
―
Wai Yuen Tong Medicine Holdings Limited
―
Lee's Pharmaceutical Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―